Identification of Rigosertib for the Treatment of Recessive Dystrophic Epidermolysis Bullosa-Associated Squamous Cell Carcinoma.
Velina S AtanasovaCeline PourreyronMehdi FarshchianMichael LawlerChristian A BrownStephen A WattSheila WrightMichael WarkalaChristina Guttmann-GruberJosefina Piñón HofbauerIgnacia FuentesMarco PriscoElham RashidghamatCristina HasJulio C Salas-AlanisFrancis PalissonAlain HovnanianJohn A McGrathJemima E MellerioJohann W BauerAndrew P SouthPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
These data support a "first in RDEB" phase II clinical trial of rigosertib to assess tumor targeting in patients with late stage, metastatic, and/or unresectable SCC.
Keyphrases
- phase ii
- clinical trial
- squamous cell carcinoma
- open label
- locally advanced
- phase iii
- double blind
- small cell lung cancer
- placebo controlled
- study protocol
- electronic health record
- lymph node metastasis
- cancer therapy
- radiation therapy
- machine learning
- bioinformatics analysis
- rectal cancer
- drug delivery
- muscular dystrophy
- deep learning
- duchenne muscular dystrophy